Dr Ranjana Pathak is President, Global Quality, Medical Affairs and Pharmacovigilance, at Cipla Limited.<br/>
At Cipla, Ranjana is part of the six-member Management Council, the apex executive leadership team of Cipla responsible for its overall vision and strategy, decision-making, and operational excellence. <br/>
As the head of Quality, Medical Affairs and Pharmacovigilance at Cipla, Ranjana oversees the execution of the entire lifecycle of a product from development to commercialisation, as well as the maintenance of an uncompromising state of control with absolute regulatory compliance across all manufacturing sites of Cipla, its partners and third parties. For Ranjana, the motto of “all-time readiness” in Quality, Safety and Compliance means an ever-vigilant Best-in-class Culture that entails a robust integration of people, products and processes at Cipla. Automation and digitisation of quality processes continue to be key areas of focus for Ranjana.<br/>
In the past, Ranjana has served several branded and generic pharmaceutical companies such as Actavis (as Senior Vice-President, Global Quality), Endo (as Vice President, Quality and Compliance), Zenith Goldline and Thames Pharmacal. With over three decades of experience in the pharmaceutical industry in the USA, Ranjana brings comprehensive expertise in quality as well as related functions, and extensive understanding of regulatory bodies such as the US FDA, MHRA, ANVISA, MCC, WHO, Europe EMA, Australia TGA among others. <br/>
Ranjana has a Doctorate in Health Administration from the University of Phoenix, USA; an MBA from Dowling College, New York; a Post-Graduate Diploma in Pharmaceutical & Chemical Analysis from Sophia College, Mumbai; and a B.Sc. (Hons) in Chemistry from Mithibai College, Mumbai.